Novo Nordisk Navigates FDA Milestone Amid Pricing Headwinds

Danish pharmaceutical giant Novo Nordisk has achieved a landmark regulatory victory with the U.S. Food and Drug Administration (FDA) granting approval for the world’s first weekly basal insulin. This breakthrough in diabetes care, however, arrives as the company contends with severe commercial pressures, including substantial price reductions in the critical U.S. market and a disappointing revenue forecast.

Strategic Diversification and Therapeutic Advance

The newly approved therapy, Awiqli, represents a significant operational achievement for Novo Nordisk. It offers adults living with type 2 diabetes a transition from daily injections to a single weekly dose, potentially improving treatment adherence. A commercial launch in the United States is scheduled for the second half of 2026.

CEO Mike Doustdar highlighted the strategic importance of this development, noting the company’s continued investment in its core insulin business even as some competitors scale back their presence. This move deliberately broadens Novo Nordisk’s portfolio beyond its well-known GLP-1 agonist drugs, such as Ozempic and Wegovy.

Mounting Commercial Pressures

The medical advancement comes at a challenging time for management. Following a failed attempt to acquire a Pfizer-owned obesity treatment startup, the firm recently issued a weak outlook that disappointed investors. For the ongoing 2026 fiscal year, the company anticipates a sales decline between 5 and 13 percent.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

A primary driver of this expected downturn is a new pricing agreement with the U.S. government. Through the direct distribution channel “TrumpRx,” the monthly prices for the blockbuster drugs Wegovy and Ozempic are plummeting from over $1,000 to just $350. This fundamental shift in the revenue model is clearly reflected in the company’s share price, which has already lost more than 52 percent of its value over the past year.

Shareholder Returns and Capital Allocation

Amid these operational challenges, recent corporate events have been closely watched by shareholders. At the annual general meeting, the board confirmed a 2.6 percent increase in the total dividend for 2025. For investors, the relevant date is today, Monday, as the stock begins trading ex-dividend. Concurrently, Novo Nordisk is supporting its share price through an ongoing buyback initiative, having already repurchased securities worth over two billion Danish kroner by the end of March.

The leadership team now faces the dual task of preparing the U.S. launch of Awiqli while managing the anticipated revenue shortfall in its GLP-1 segment caused by the new American pricing deal. The final dividend payment to shareholders of record is set for distribution on April 8, 2026.